Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum
Abstract A total of 129 symptomatic patients with multiple myeloma (MM) who underwent high‐dose chemotherapy with autologous stem cell transplantation (HDT/ASCT) were analyzed. The 4‐year overall survival (OS) of patients with maintenance (n = 82) was 80%, whereas that of patients without maintenanc...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-11-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.284 |
| _version_ | 1797740139740397568 |
|---|---|
| author | Aya Nakaya Hirohiko Shibayama Eiji Nakatani Yuji Shimura Satoru Kosugi Hirokazu Tanaka Shin‐Ichi Fuchida Junya Kanda Nobuhiko Uoshima Hitomi Kaneko Kazunori Imada Kensuke Ohta Tomoki Ito Hideo Yagi Satoshi Yoshihara Masayuki Hino Chihiro Shimazaki Akifumi Takaori‐Kondo Junya Kuroda Itaru Matsumura Yuzuru Kanakura Shosaku Nomura |
| author_facet | Aya Nakaya Hirohiko Shibayama Eiji Nakatani Yuji Shimura Satoru Kosugi Hirokazu Tanaka Shin‐Ichi Fuchida Junya Kanda Nobuhiko Uoshima Hitomi Kaneko Kazunori Imada Kensuke Ohta Tomoki Ito Hideo Yagi Satoshi Yoshihara Masayuki Hino Chihiro Shimazaki Akifumi Takaori‐Kondo Junya Kuroda Itaru Matsumura Yuzuru Kanakura Shosaku Nomura |
| author_sort | Aya Nakaya |
| collection | DOAJ |
| description | Abstract A total of 129 symptomatic patients with multiple myeloma (MM) who underwent high‐dose chemotherapy with autologous stem cell transplantation (HDT/ASCT) were analyzed. The 4‐year overall survival (OS) of patients with maintenance (n = 82) was 80%, whereas that of patients without maintenance (n = 47) was 72% (p = 0.426). The 4‐year progression‐free survival (PFS) of patients with maintenance was 38%, whereas that of patients without maintenance was 27% (p = 0.088). Multivariate analysis revealed that an International Staging System score ≥2 was associated with worse PFS (hazard ratio 1.62, p = 0.043). Among the 129 patients, two were excluded owing to early relapse, 50 patients achieved complete response (CR), and 77 patients failed to achieve CR. Patients who achieved CR showed better 4‐year PFS than those who failed to achieve CR (41% vs. 30%, p = 0.027); however, 4‐year OS was not different (76% vs. 82%, p = 0.971). In patients who achieved CR, 4‐year OS with/without maintenance was 74%/81% (p = 0.357), 4‐year PFS with/without maintenance was 42%/40% (p = 0.954). In patients who failed to achieve CR, the 4‐year OS with/without maintenance was 97%/91% (p = 0.107), and 4‐year PFS with/without maintenance was 36%/16% (p < 0.001). In patients who failed to achieve CR, maintenance significantly improved the PFS. Maintenance after HDT/ASCT can prolong PFS in patients who fail to achieve CR in real‐world settings. |
| first_indexed | 2024-03-12T14:07:15Z |
| format | Article |
| id | doaj.art-fca8d9086da64417a2e3ae2412495e6f |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-12T14:07:15Z |
| publishDate | 2021-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-fca8d9086da64417a2e3ae2412495e6f2023-08-21T14:05:23ZengWileyeJHaem2688-61462021-11-012476577310.1002/jha2.284Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma ForumAya Nakaya0Hirohiko Shibayama1Eiji Nakatani2Yuji Shimura3Satoru Kosugi4Hirokazu Tanaka5Shin‐Ichi Fuchida6Junya Kanda7Nobuhiko Uoshima8Hitomi Kaneko9Kazunori Imada10Kensuke Ohta11Tomoki Ito12Hideo Yagi13Satoshi Yoshihara14Masayuki Hino15Chihiro Shimazaki16Akifumi Takaori‐Kondo17Junya Kuroda18Itaru Matsumura19Yuzuru Kanakura20Shosaku Nomura21First Department of Internal Medicine Kansai Medical University Osaka JapanDepartment of Hematology and Oncology Osaka University Graduate School of Medicine Osaka JapanGraduate School of Public Health Shizuoka Graduate University of Public Health Shizuoka JapanDivision of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Kyoto JapanDepartment of Internal Medicine (Hematology) Toyonaka Municipal Hospital Osaka JapanDepartment of Hematology and Rheumatology Kindai University Faculty of Medicine Osaka JapanDepartment of Hematology Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center Kyoto JapanDepartment of Hematology and Oncology, Graduate School of Medicine Kyoto University Kyoto JapanDepartment of Hematology Japanese Red Cross Kyoto Daini Hospital Kyoto JapanDepartment of Hematology Japanese Red Cross Osaka Hospital Osaka JapanDepartment of Hematology Japanese Red Cross Osaka Hospital Osaka JapanHematology Ohta Clinic Shinsaibashi Osaka JapanFirst Department of Internal Medicine Kansai Medical University Osaka JapanDepartment of Hematology and Oncology Nara Prefecture General Medical Center Nara JapanDivision of Hematology, Department of Internal Medicine Hyogo College of Medicine Hyogo JapanDepartment of Hematology Osaka City University Graduate School of Medicine Osaka JapanDepartment of Hematology Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center Kyoto JapanDepartment of Hematology and Oncology, Graduate School of Medicine Kyoto University Kyoto JapanDivision of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Kyoto JapanDepartment of Hematology and Rheumatology Kindai University Faculty of Medicine Osaka JapanDepartment of Hematology Sumitomo Hospital Osaka JapanFirst Department of Internal Medicine Kansai Medical University Osaka JapanAbstract A total of 129 symptomatic patients with multiple myeloma (MM) who underwent high‐dose chemotherapy with autologous stem cell transplantation (HDT/ASCT) were analyzed. The 4‐year overall survival (OS) of patients with maintenance (n = 82) was 80%, whereas that of patients without maintenance (n = 47) was 72% (p = 0.426). The 4‐year progression‐free survival (PFS) of patients with maintenance was 38%, whereas that of patients without maintenance was 27% (p = 0.088). Multivariate analysis revealed that an International Staging System score ≥2 was associated with worse PFS (hazard ratio 1.62, p = 0.043). Among the 129 patients, two were excluded owing to early relapse, 50 patients achieved complete response (CR), and 77 patients failed to achieve CR. Patients who achieved CR showed better 4‐year PFS than those who failed to achieve CR (41% vs. 30%, p = 0.027); however, 4‐year OS was not different (76% vs. 82%, p = 0.971). In patients who achieved CR, 4‐year OS with/without maintenance was 74%/81% (p = 0.357), 4‐year PFS with/without maintenance was 42%/40% (p = 0.954). In patients who failed to achieve CR, the 4‐year OS with/without maintenance was 97%/91% (p = 0.107), and 4‐year PFS with/without maintenance was 36%/16% (p < 0.001). In patients who failed to achieve CR, maintenance significantly improved the PFS. Maintenance after HDT/ASCT can prolong PFS in patients who fail to achieve CR in real‐world settings.https://doi.org/10.1002/jha2.284autologous stem cell transplantationlenalidomidemaintenance therapyretrospectivesymptomatic multiple myeloma |
| spellingShingle | Aya Nakaya Hirohiko Shibayama Eiji Nakatani Yuji Shimura Satoru Kosugi Hirokazu Tanaka Shin‐Ichi Fuchida Junya Kanda Nobuhiko Uoshima Hitomi Kaneko Kazunori Imada Kensuke Ohta Tomoki Ito Hideo Yagi Satoshi Yoshihara Masayuki Hino Chihiro Shimazaki Akifumi Takaori‐Kondo Junya Kuroda Itaru Matsumura Yuzuru Kanakura Shosaku Nomura Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum eJHaem autologous stem cell transplantation lenalidomide maintenance therapy retrospective symptomatic multiple myeloma |
| title | Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum |
| title_full | Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum |
| title_fullStr | Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum |
| title_full_unstemmed | Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum |
| title_short | Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum |
| title_sort | significance of maintenance therapy after hdt asct in symptomatic multiple myeloma a multicenter retrospective analysis in kansai myeloma forum |
| topic | autologous stem cell transplantation lenalidomide maintenance therapy retrospective symptomatic multiple myeloma |
| url | https://doi.org/10.1002/jha2.284 |
| work_keys_str_mv | AT ayanakaya significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT hirohikoshibayama significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT eijinakatani significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT yujishimura significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT satorukosugi significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT hirokazutanaka significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT shinichifuchida significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT junyakanda significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT nobuhikouoshima significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT hitomikaneko significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT kazunoriimada significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT kensukeohta significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT tomokiito significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT hideoyagi significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT satoshiyoshihara significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT masayukihino significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT chihiroshimazaki significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT akifumitakaorikondo significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT junyakuroda significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT itarumatsumura significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT yuzurukanakura significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum AT shosakunomura significanceofmaintenancetherapyafterhdtasctinsymptomaticmultiplemyelomaamulticenterretrospectiveanalysisinkansaimyelomaforum |